Identification of a Putative Syp Substrate, the PDGFβ Receptor (*)
- From the National Jewish Center for Immunology and Respiratory Medicine, Division of Basic Sciences, Denver, Colorado 80206 and the University of Colorado Health Sciences Center, Department of Pharmacology, Denver, Colorado 80262
- § Established Investigator of the American Heart Association. To whom correspondence should be addressed. National Jewish Center for Immunology and Respiratory Medicine, Division of Basic Sciences, 1400 Jackson St., Denver, CO 80206. Tel.: 303-398-1454; Fax: 303-398-1225; kazlauskasa{at}njc.org
Abstract
Because the protein-tyrosine phosphatase (PTP) Syp associates with the tyrosine-phosphorylated platelet-derived growth factor β receptor (βPDGFR), the βPDGFR is a likely Syp substrate. We tested this hypothesis by determining whether recombinant Syp (rSyp) and a control PTP, recombinant PTP1B (rPTP1B), were able to dephosphorylate the βPDGFR. The βPDGFR was phosphorylated at multiple tyrosine residues in an in vitro kinase assay and then incubated with increasing concentrations of rSyp or rPTP1B. While the receptor was nearly completely dephosphorylated by high concentrations of rPTP1B, receptor dephosphorylation by rSyp plateaued at approximately 50%. Two-dimensional phosphopeptide maps of the βPDGFR demonstrated that rSyp displayed a clear preference for certain receptor phosphorylation sites; the most efficiently dephosphorylated sites were phosphotyrosines (Tyr(P))-771 and −751, followed by Tyr(P)-740, while Tyr(P)-1021 and Tyr(P)-1009 were very poor substrates. In contrast, rPTP1B displayed no selectivity for the various βPDGFR tyrosine phosphorylation sites and dephosphorylated all of them with comparable efficiency. A Syp construct that lacked the SH2 domains was still able to discriminate between the various receptor phosphorylation sites, although less effectively than full-length Syp.
These in vitro studies predicted that Syp can dephosphorylate the receptor in vivo. Indeed, we found that a βPDGFR mutant (F1009) that associates poorly with Syp, had a much slower in vivo rate of receptor dephosphorylation than the wild type receptor. In addition, the GTPase-activating protein of Ras (GAP) and phosphatidylinositol 3-kinase were less stably associated with the wild type βPDGFR than with the F1009 receptor. These findings are consistent with the in vitro experiments showing that Syp prefers to dephosphorylate sites on the βPDGFR, that are important for binding phosphatidylinositol 3-kinase (Tyr(P)-740 and Tyr(P)-751) and GAP (Tyr(P)-771). These studies reveal that Syp is a substrate-selective PTP and that both the catalytic domain and the SH2 domains contribute to Syp's ability to choose substrates. Furthermore, it appears that Syp plays a role in PDGF-dependent intracellular signal relay by selectively dephosphorylating the βPDGFR and thereby regulating the binding of a distinct group of receptor-associated signal relay enzymes.
Footnotes
-
↵* This work was supported by National Institutes of Health Grants CA55063, GM48339, and CA58187. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
-
↵1 The abbreviations used are:
- PTP
-
protein-tyrosine phosphatase
- MAP
-
mitogen-activated protein
- GAP
-
GTPase-activating protein
- PI
-
phosphatidylinositol
- PCR
-
polymerase chain reaction
- PAGE
-
polyacrylamide gel electrophoresis
- pNPP
-
para-nitrophenyl phosphate
- WT
-
wild type
- PDGF
-
platelet-derived growth factor
- PDGFR
-
PDGF receptor.
-
↵2R. A. Klinghoffer and A. Kazlauskas, unpublished observations.
-
- Received December 29, 1994.
- Revision received June 16, 1995.
- © 1995 by The American Society for Biochemistry and Molecular Biology, Inc.











